Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh. original article: UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes – CBS Pittsburgh (cbsnews.com)
Genprex said that after receiving the US Food and Drug Administration's fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.
Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.
Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.
The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.
Five companies in the past week reported more than $54 million in funding deals and securities offerings.
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.
How gene therapy is reprogramming the course of lung cancer.
Lead product, Oncoprex, is an injectable treatment for lung cancer.
Designed and Secured by Barsec